Crystalline forms of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof
AssigneevTv Therapeutics LLC
InventorsJing Teng, Yizheng Cao
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a) crystalline forms of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazo 1-5-ylsulfanyl}-acetic acid (“Compound I”); b) pharmaceutical compositions, comprising one or more crystalline forms of Compound I, and optionally, a pharmaceutically acceptable carrier; c) methods of treating a type of diabetes mellitus or other disorders by administering one or more crystalline forms of Compound I; and d) methods for the preparation of crystalline forms of Compound I.
Claims5
An anhydrous crystalline form of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid that is characterized as having:
- an X-ray powder diffraction (XRPD) comprising peaks at the following diffraction angles:
- 11.0+0.2, 11.6 +0.2, and 17.8 +0.2 degrees two theta as measured using Cu, Kα radiation (Form B);
- and (i) an endothermic peak with onset at about 166° C., as determined by Differential Scanning Calorimetry (DSC), or (ii) an Infrared Spectroscopy (IR) pattern having peaks at 1310.1±2.0, 1514.4±2.0, and 1661.3±12.0cm-1;
- and a polymorphic purity of at least 95%;
- or
- an XRPD comprising peaks at the following diffraction angles:
- 5.3±0.2, 8.7±0.2, and 26.4±0.2 degrees two theta as measured using Cu, Kα radiation (Form D);
- an endothermic peak with onset at about 147° C., as determined by DSC;
- and a polymorphic purity of at least 95%;
- or
- an XRPD comprising peaks at the following diffraction angles:
- 5.8±0.2, 17.9±0.2, and 18.9±0.2 degrees two theta as measured using Cu, Kα radiation (Form E);
- an endothermic peak with onset at about 171° C., as determined by DSC;
- and a polymorphic purity of at least 95%.
A crystalline form of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid comprising Crystalline Form A and either Crystalline Form B or Crystalline Form E, wherein Crystalline Form A is characterized as having an X-ray powder diffraction (XRPD) comprising peaks at the following diffraction angles:
- 8.7±0.2, 16.9±0.2, 17.4±0.2, and 20.1±0.2 degrees two theta as measured using Cu, Kα radiation (Form A);
- and an endothermic peak with onset at about 160° C., as determined by Differential Scanning Calorimetry (DSC);
- wherein Crystalline Form B is characterized as having an XRPD comprising peaks at the following diffraction angles:
- 11.0±0.2, 11.6±0.2, 17.8±0.2, and 21.1±0.2 degrees two theta as measured using Cu, Kα radiation (Form B);
- and an endothermic peak with onset at about 166° C., as determined by DSC;
- and
- wherein Crystalline Form E is characterized as having an XRPD comprising peaks at the following diffraction angles:
- 5.8±0.2, 17.9±0.2, 18.9±0.2, and 20.7±0.2 degrees two theta as measured using Cu, Kα radiation (Form E);
- and an endothermic peak with onset at about 171° C., as determined by DSC.
Dependencies are inferred from the claim text.